Lobradimil（RMP ...

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on PHVS stock, giving a Buy rating yesterday.Stay Ahead of the ...

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies ...

13, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living ...

Drugs in this class also decrease ACE-dependent degradation of substance P and bradykinin ... between CRPS and the use of angiotensin-II-receptor blockers. These antihypertensive drugs elicit ...

The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft ...